Kaye Jack’s Dual Move: Insider Buys UNIQURE at €16, Sells at €30 Amid Volatile Gene‑Therapy Stock Flash!

Insider Buying in a Volatile Market

On 3 June 2026 Kaye Jack executed a Rule 10b‑5‑1 compliant purchase of 2 645 ordinary shares of UNIQURE NV at €16.04 each, adding to an existing stake of 20 439 shares. The transaction is part of a pre‑planned sales plan adopted on 16 June 2025. In the same filing Jack also sold 2 645 shares at €30.01 and liquidated a stock‑option position, leaving her post‑trade holding at 23 084 shares. The buy order, priced well below the close of €23.35, signals a willingness to add position despite the company’s sharp weekly (≈31 %) and monthly (≈61 %) rally, and an annual upside of more than 80 %.

Implications for Investors

The timing is telling: the sale plan is executed exactly when the stock’s price is near a 52‑week low of €7.26 and the company is approaching its 52‑week high of €60.50. Investors may interpret the purchase as a “buy the dip” tactic, indicating confidence that the company’s long‑term prospects – gene‑therapy pipelines for hemophilia B and Huntington’s disease – will justify a higher valuation. However, the simultaneous sale at €30.01 hints that Jack may be balancing liquidity needs or hedging against a potential short‑term correction. In the current environment of high volatility and regulatory scrutiny, such dual transactions can be perceived as neutral or even bullish, depending on how the market decodes the underlying motives.

Kaye Jack’s Insider Profile

Jack’s transaction history shows a pattern of disciplined, rule‑based trading. In January 2026 she bought 6 390 shares at €19.39 and sold an equal amount at €27.28, then sold a stock option at zero cost – a textbook 10b‑5‑1 plan. The June buy is consistent with this pattern: a systematic acquisition at a lower price point, paired with a sale at a higher price. Her holdings have oscillated between roughly 20 000 and 30 000 shares, suggesting she maintains a significant but not controlling stake. This behavior reflects a long‑term view rather than short‑term speculation, reinforcing the narrative that the company’s future gene‑therapy developments remain attractive to insiders.

What It Means for UNIQURE’s Future

UNIQURE’s market cap of €1.73 billion and negative P/E of –8.51 reflect the valuation pressure typical of biotech firms still in the development phase. The recent insider activity, combined with a robust clinical pipeline and a solid regulatory track record, could temper market skepticism. If the company continues to progress clinical milestones, insider buying may reinforce a positive sentiment and help sustain the recent upward trajectory. Conversely, any setbacks could expose the company to the same liquidity pressures that prompted Jack’s partial sales. Investors should watch for the next quarterly report and any FDA or EMA announcements, which will be the real gauge of whether this insider confidence translates into shareholder value.